CETP and familial hypercholesterolemia: Anacetrapib is an inhibitor of CETP, which can lead to impressive changes of the serum lipid profile, as shown in Table 1, which includes the results of the REVEAL trial and two randomized trials that evaluated the efficacy of the drug in both high-risk patients, as well as in patients with familial hypercholesterolemia [9,10,11].